leisure time -WSS

leisure time

author：knowledge 2025-08-26 10:51:52 - browse：965

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Why you get paid to donate plasma but not blood

WSS

Why you get paid to donate plasma but not blood

A strong 6.5

Boston hospital trains restaurant workers on naloxone for overdoses

Fertility clinic egg and embryo storage is a disaster

As H5N1 spreads in cows, experts warn against drinking raw milk

Why you get paid to donate plasma but not blood

hotspot

leisure time

hotspot

Drug repurposing or repositioning? The language matters

STAT reporters are Pulitzer Prize finalists for investigative reporting

Tori Bowie and the unacceptable rates of Black maternal death

STAT series 'Denied by AI' wins major journalism prizes

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

How one medical school became remarkably diverse

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

focus

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

CVS is willing to dump 10% of its Medicare Advantage members

Lack of darker skin in textbooks, journals harms patients of color

UK homeowners get some respite as inflation falls by more than anticipated to a 15

What we know about the American soldier detained in North Korea

Wikipedia

explore

focus

hotspot